Consistently, analysis performed across all TCGA tumors shows that RIPK3 has a positive correlation and TRIM28 has a negative correlation with CD8+ T cells and DCs infiltrating tumor tissues, while TRIM28 has a negative correlation (Fig. 7h), thus implying that the deregulation of TRIM28 by activated-RIPK3 can enhance immunogenicity in the tumor and could be an important combination strategy with current T-cell-based immunotherapy. The gene discussed is TRIM28; the disease is neoplasm.